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Abstract
Gene transfer of basic fibroblast growth factor (bFGF) 
has been shown to induce significant endothelial mi-
gration and angiogenesis in ischemic disease models. 
Here, we investigate what factors are secreted from 
skeletal muscle cells (SkMCs) transfected with bFGF 
gene and whether they participate in endothelial cell 
migration. We constructed replication-defective ad-
enovirus vectors containing the human bFGF gene 
(Ad/bFGF) or a control LacZ gene (Ad/LacZ) and ob-
tained conditioned media, bFGF-CM and LacZ-CM, 
from SkMCs infected by Ad/bFGF or Ad/LacZ, 
respectively. Cell migration significantly increased in 
HUVECs incubated with bFGF-CM compared to cells 
incubated with LacZ-CM. Interestingly, HUVEC migra-
tion in response to bFGF-CM was only partially blocked 
by the addition of bFGF-neutralizing antibody, sug-
gesting that bFGF-CM contains other factors that stim-
ulate endothelial cell migration. Several proteins, ma-
trix metalloproteinase-1 (MMP-1), plasminogen activa-
tor inhibitor-1 (PAI-1), and cathepsin L, increased in 
bFGF-CM compared to LacZ-CM; based on 1-dimen-
sional gel electrophoresis and mass spectrometry. 
Their increased mRNA and protein levels were con-
firmed by RT-PCR and immunoblot analysis. The re-
combinant human bFGF protein induced MMP-1, 
PAI-1, and cathepsin L expression in SkMCs. 
Endothelial cell migration was reduced in groups treat-
ed with bFGF-CM containing neutralizing antibodies 
against MMP-1 or PAI-1. In particular, HUVECs treated 
with bFGF-CM containing cell-impermeable cathepsin 
L inhibitor showed the most significant decrease in cell 
migration. Cathepsin L protein directly promotes en-
dothelial cell migration through the JNK pathway. 
These results indicate that cathepsin L released from 
SkMCs transfected with the bFGF gene can promote 
endothelial cell migration.
Keywords: fibroblast growth factor 2; cathepsin L; en-
dothelium; JNK Mitogen-Activated Protein Kinases; 
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Introduction
Angiogenesis is the biological process of growing 
new blood vessels from preexisting vessels, which 
involves the disruption of the extracellular matrix 
(ECM) by proteolytic enzymes, endothelial cell 
proliferation and migration, and the subsequent 
formation and maturation of new capillary tubes 
(Markkanen et al., 2005; Chen et al., 2009). Endo-
thelial cell migration is essential to angiogenesis, 
which is regulated by chemotactic, haptotactic, and 
mechanotactic stimuli (Lamalice et al., 2007). 
Chemotactic endothelial cell migration is asso-
180    Exp. Mol. Med. Vol. 43(4), 179-188, 2011
ciated with several growth factors, such as vascular 
endothelial growth factor (VEGF), bFGF, and other 
cytokines (Lamalice et al., 2007; Chen et al., 2010; 
Kim et al., 2010). Although several growth factors 
contribute to proliferative and migratory events, 
bFGF plays a key role in endothelial cell migration 
through its cognate receptor and intracellular 
signaling response (Pintucci et al., 2002). Also, 
bFGF has a wide spectrum of target cells, 
including smooth muscle cells, fibroblasts, kerati-
nocytes, and SkMCs involved in diverse biological 
responses (Barrientos et al., 2008), suggesting that 
endothelial cell migration is probably regulated by 
communication between the endothelium and the 
surrounding environment.
    Proteases are also involved in normal physio-
logical processes, including angiogenesis and vas-
culogenesis (van Hinsbergh et al., 2006). Among 
them, three groups of endoproteases are known to 
play a crucial role in the regulatory pathways that 
control various processes of angiogenesis such as 
endothelial cell migration, invasion, and remodeling 
of the extracellular matrix. These endoproteases 
comprise the zinc-dependent MMPs, the serine 
proteases such as uPA, and cathepsin cysteine 
proteases. It has been extensively studied that MMPs 
are the key molecules associated with tissue re-
modeling and wound healing response as well as 
cell migration and invasion (Le et al., 2007). Serine 
proteases such as uPA and plasmin have also 
been reported to modulate cellular adhesion and 
migration in various physiological conditions (D'Alessio 
and Blasi, 2009). Another family of proteases con-
sists of the cysteine cathepsins which are expressed 
in the cell surface and secreted into the extra-
cellular space (Palermo and Joyce, 2008). Cathep-
sins have recently emerged as an important class 
of proteolytic enzymes in cell migration and inva-
sion. Cathepsin L, in particular, has broad sub-
strate specificity and activates several molecules 
involved in angiogenesis (Stoka et al., 2007). 
Cathepsin L induces the ECM degradation (Gocheva 
and Joyce, 2007) and stimulates the recruitment 
and action of blood-derived accessory cells that 
enhance angiogenesis (van Hinsbergh et al., 2006).
    Because gene delivery using growth factors has 
been shown to induce beneficial effects in animal 
models (Yla-Herttuala, 2006), angiogenic gene the-
rapy can be a reasonable strategy to achieve the 
same effects. The therapeutic potential of bFGF 
gene delivery has also been confirmed in myocardial 
and limb ischemia models (Ninomiya et al., 2003; 
Kondoh et al., 2004). In most cases of therapeutic 
gene delivery, an expression vector harboring target 
genes is injected intramuscularly, and the exogenous 
gene is expressed mainly in the muscle cells. In 
the in vivo angiogenic gene transfer approach, a 
foreign gene is expressed in non-endothelial cells 
and the angiogenic process is regulated by the 
participation of multiple factors from several cells. 
Therefore, the paracrine actions of other factors 
secreted from non-endothelial cells together with 
the direct effects of the therapeutic gene seem to 
be a sound mechanism to explain the improved 
functional outcomes in therapeutic angiogenesis 
trials. In previous studies using limb ischemia animal 
models, intramuscular injections of the bFGF gene 
showed increased expression of hepatocyte growth 
factor (Onimaru et al., 2002) and placenta growth 
factor (Fujii  et al., 2008). This suggests another 
mechanism for the increase of angiogenesis with 
bFGF gene transfer is the secretion of several 
factors from non-endothelial cells, including SkMCs. 
However, little is known about the expression of 
growth factors and cytokines stimulated by bFGF 
in skeletal muscle, which is a target tissue of gene 
delivery for limb diseases. Thus, we sought to 
identify novel factors secreted from SkMCs trans-
fected with bFGF that contribute to endothelial cell 
migration in vitro. In the present study, we tested 
what factors are secreted from SkMCs with Ad/ 
bFGF transfection and whether they participate in 
endothelial cell migration associated with angio-
genesis. 
Results
bFGF expression in skeletal muscle cells
Human SkMCs were infected with a replication- 
defective adenoviral vector (Ad/bFGF) containing 
the human bFGF gene. After 72 h, the level of 
bFGF expression was evaluated by reverse trans-
criptase-polymerase chain reaction (RT-PCR). The 
bFGF expression from the Ad/bFGF-infected cells 
was significantly higher than the LacZ gene- 
containing adenoviral vector (Ad/LacZ)-infected 
cells or the blank group (uninfected cells) (Figure 
1A). Secretion of bFGF protein from Ad/bFGF- 
infected cells was detected by immunoblot analysis. 
The level of bFGF protein was significantly greater 
in SkMC media infected with Ad/bFGF than in 
SkMC media infected with Ad/LacZ (Figure 1B). 
These results demonstrate that a recombinant 
adenoviral vector harboring the bFGF gene could 
successfully transfer into cells and efficiently pro-
duce the bFGF protein in SkMCs. The amount of 
bFGF protein secreted from Ad/bFGF-infected cells 
increased in a time-dependent manner (Figure 1C). 
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Figure 1. bFGF expression and secretion in the SkMCs infected with 
Ad/bFGF. (A) SkMCs were transfected with Ad/LacZ or Ad/bFGF. After 
72 h, total RNA was isolated from SkMCs and RT-PCR was performed. 
(B) The culture media from cells trasfected with Ad/LacZ or Ad/bFGF and 
uninfected cells (Blank) were collected. Equal amounts of protein were 
separated by SDS-PAGE, and bFGF protein was detected by immuno-
blot analysis using anti-bFGF antibody. (C) The amount of bFGF se-
creted from cultured SkMCs was measured with the human bFGF ELISA 
kit. The results represent the means± SEM of five different experiments.
Figure 2. Effect of bFGF-CM on HUVECs migration. (A) HUVEC migra-
tion was stimulated by addition of basal media, conditioned medium from 
uninfected SkMCs (Control CM), conditioned medium from SkMCs trans-
fected with Ad/LacZ (LacZ-CM) or conditioned medium from SkMCs 
transfected with Ad/bFGF (bFGF-CM). After 12 h, cells that migrated to 
the other side of the membrane in Boyden chamber were stained with 
1% crystal violet and eluted with methanol, and quantitative analyses 
were performed by optical density. The results represent the means±
SEM of three different experiments. *P＜ 0.01 compared to LacZ-CM 
group. (B) HUVEC migration was stimulated by addition of LacZ-CM, 
bFGF-CM or bFGF protein (2 ng/ml, in basal media). The bFGF-neutral-
izing antibody (3 μg/ml) was co-treated to the chamber. After 12 h, mi-
grated cells were stained and quantified. The results represent the 
means± SEM of three different experiments. *P＜ 0.01.
Effect of bFGF-conditioned SkMC medium on 
endothelial cell migration
We examined the effect of bFGF-CM collected 
from SkMCs infected with Ad/bFGF on endothelial 
cell migration. The effect of bFGF-CM on endo-
thelial cell migration was determined by Boyden 
chamber migration assay. When HUVECs were 
incubated with bFGF-CM (50% in basal medium), 
cell migration significantly increased compared to 
cells incubated with LacZ-conditioned medium 
(LacZ-CM, 50% in basal medium) (Figure 2A). To 
determine whether this significant increase can be 
attributed exclusively to the effect of bFGF protein 
in bFGF-CM, we analyzed endothelial migration 
using a bFGF-neutralizing antibody. The addition of 
exogenous bFGF protein (2 ng/ml) to basal culture 
medium accelerated cell migration and the addition 
of bFGF-neutralizing antibody completely prevented 
endothelial cell migration (Figure 2B). However, 
HUVEC migration in response to bFGF-CM was 
only partially blocked by the addition of a bFGF- 
neutralizing antibody (Figure 2B). The bFGF-CM- 
induced HUVEC migration was not totally inhibited 
even at higher concentrations of the bFGF- 
neutralizing antibody (more than 10 μg/ml) (data 
not shown). The addition of a control IgG antibody 
did not change the cell migration of the bFGF 
protein-treated group or bFGF-CM-treated group 
(data not shown). From these data, we infer that 
bFGF-CM contains other factors, in addition to 
bFGF, that stimulate endothelial cell migration.
Identification of factors in bFGF-CM of SkMCs
We decided to identify other factors besides bFGF 
in bFGF-CM using a proteomic strategy. To identify 
endothelial migration factors secreted from SkMCs 
infected with Ad/bFGF, both conditioned media 
(LacZ-CM or bFGF-CM) were harvested and con-
centrated, and proteins were analyzed by 8-16% 
one-dimensional gradient SDS-PAGE and silver 
staining. Individual protein bands were excised 
from the stained gel and digested by trypsin, and 
the resulting peptides were analyzed by mass 
spectrometer (Supplementary Figure 1). As expected, 
β-galactosidase and bFGF bands were found in 
LacZ-CM and bFGF-CM, respectively (Figure 3A). 
Our analysis revealed that several proteins, MMP-1, 
PAI-1, cathepsin L, moesin and cyclophilin B, in-
creased in bFGF-CM compared to LacZ-CM (Figure 
3A). No protein was identified in a 90-kDa band. In 
order to quantitatively confirm the changes of in 
expression level, mRNA levels of several factors 
identified by mass spectrometry were measured 
using RT-PCR. The mRNA levels of three factors, 
MMP-1, PAI-1, and cathepsin L, were remarkably 
increased in SkMCs infected with Ad/bFGF com-
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Figure 3. Analysis of factors secreted from SkMCs transfected with bFGF. (A) SkMCs were transfected with 
Ad/LacZ or Ad/bFGF. After 72 h, each conditioned media were concentrated ten times, and secreted proteins were 
analyzed by 8-16% gradient SDS-PAGE. Proteins separated by SDS-PAGE were subjected to in-gel digestion by 
trypsin and analyzed by MALDI-TOF mass spectrometry. (B) SkMCs were transfected with Ad/LacZ or Ad/bFGF. 
After 72 h, total RNA was isolated from SkMCs and RT-PCR was performed. The PCR products were electro-
phoresed on 1.5% agarose gel. Bands were quantified by densitometry, and the values were normalized to that of 
β-actin mRNA. Blank, RT-PCR band from uninfected cells. *P＜ 0.01 compared to the blank (uninfected cells). 
(C) SkMCs were transfected with Ad/LacZ or Ad/bFGF. After 72 h, culture media were collected and concentrated 
ten times. Equal amounts of protein were separated by SDS-PAGE and analyzed by immunoblot assay. 
pared to Ad/LacZ-infected cells (Figure 3B). The 
protein levels were the same in the culture medium 
(bFGF-CM) of SkMCs infected with Ad/bFGF 
(Figure 3C). There was little difference in the 
mRNA and protein levels of other factors (moesin 
and cyclophilin B) between the Ad/LacZ and Ad/ 
bFGF groups (data not shown). 
bFGF induces expression of three factors in SkMCs
The expression of three factors in SkMCs infected 
with Ad/bFGF suggests they were released by the 
autocrine effect of bFGF in response to the bFGF 
gene transfer into the SkMCs. To test this hypo-
thesis, SkMCs were stimulated with bFGF protein 
and the mRNA level in the cells and the protein 
level in the media were measured by RT-PCR and 
ELISA, respectively. As shown in Figure 4A, re-
combinant human bFGF protein induced the expre-
ssion of MMP-1, PAI-1 and cathepsin L. Corres-
ponding to the mRNA levels, the bFGF protein 
treatment significantly increased the amount of 
these factors in cell culture media (Figure 4B). 
Hence, these results suggest that the production of 
these factors may result from the autocrine effect 
in response to the bFGF released from SkMCs 
transfected with bFGF gene.
Cathepsin L in bFGF-CM of SkMC is critical for 
endothelial cell migration   
To determine whether these factors released from 
the bFGF-CM of SkMC contribute to endothelial 
cell migration, we examined the migration of 
HUVECs by treating them with bFGF-CM containing 
neutralizing antibodies or a chemical inhibitor. Cell 
migration was significantly reduced when the 
HUVECs were treated with bFGF-CM containing 
MMP-1 neutralizing antibody (Figure 5A) compared 
to treatment with bFGF-CM alone. Cell migration 
also slightly decreased in the PAI-1 neutralizing 
antibody-treated bFGF-CM group. In particular, 
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Figure 4. Expression and secretion of MMP-1, PAI-1 and cathepsin L by bFGF protein treatment in SkMCs. (A) 
SkMCs were treated with bFGF protein (1 or 10 ng/ml). After 24 h, total RNA was isolated from SkMCs and 
RT-PCR was performed. The PCR products were electrophoresed on 1.5% agarose gel. Bands were quantified by 
densitometry, and the values were normalized to that of β-actin mRNA. *P＜ 0.01 compared to the control. (B) 
The amount of MMP-1, PAI-1 and cathepsin L secreted from cultured SkMCs was measured using ELISA kits. The 
results represent the means± SEM of five different experiments. *P＜ 0.01 compared to the control.
Figure 5. Effect of cathepsin L inhibitor on the bFGF-CM-induced 
HUVECs migration. (A) HUVECs were incubated with bFGF-CM alone or 
medium containing MMP-1 neutralizing antibody (5 μg/ml), PAI-1 neutral-
izing antibody (5 μg/ml), or cathepsin L inhibitor (200 nM) for 12 h. 
Migrated cells were stained and quantified. The results represent the 
means± SEM of three different experiments. 1, LacZ-CM; 2, bFGF-CM;
3, bFGF-CM + MMP-1 neutralizing Ab (5 μg/ml); 4, bFGF-CM + PAI-1 
neutralizing Ab (5 μg/ml); 5, bFGF-CM + Cathepsin L inhibitor (200 nM). 
*P＜ 0.05 compared to the bFGF-CM group. **P＜ 0.01 compared to 
the bFGF-CM group. (B) HUVECs were incubated with bFGF-CM con-
taining different concentration of cathepsin L inhibitor in Boyden chamber 
for 12 h. Cell migration assay was also performed in the same way as 
above. The results represent the means± SEM of three different 
experiments. *P＜ 0.01 compared to the bFGF-CM group.
HUVECs treated with bFGF-CM containing cell- 
impermeable cathepsin L inhibitor (Z-Phe-Tyr-CHO) 
showed the most significant decrease in cell 
migration (Figure 5A); this occurred in a concentration- 
dependent manner (Figure 5B).
Cathepsin L induces endothelial cell migration via 
c-Jun N-terminal kinase (JNK)   
Next, we studied whether indeed the three factors 
directly stimulate endothelial cell migration. The 
HUVECs were exposed to MMP-1, PAI-1, or 
cathepsin L for 12 h and a Boyden chamber assay 
was performed. We observed that MMP-1 treat-
ment resulted in an increase of HUVEC migration 
in a concentration-dependent manner (Figure 6A). 
Only a slight increase in cell migration was found 
after treatment with PAI-1. Of the three factors, 
cathepsin L is the most effective in stimulating 
HUVEC migration; compared to the control, it 
stimulated endothelial cell migration from 2.2- to 
3.9-fold at concentrations of 10 and 100 ng/ml, 
respectively (Figure 6A). To characterize the intra-
cellular signaling pathways that mediate the effects 
of cathepsin L on endothelial cell migration, we 
focused on MAP kinases because of their involve-
ment in regulating cell migration in several cell 
types, including endothelial cells. We found that 
cathepsin L induced phosphorylation of JNK in 
HUVECs in a concentration-dependent manner 
(Figure 6B). The protein levels of total JNK were 
unchanged for all concentrations of cathepsin L 
(data not shown). We next examined whether a 
JNK-specific inhibitor could prevent cathepsin L- 
induced endothelial cell migration. As shown in 
Figure 6C, treatment with the JNK-specific inhibitor, 
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Figure 6. Effect of cathepsin L on HUVEC migration. (A) HUVEC migration was stimulated by addition of MMP-1, PAI-1 or cathepsin L. After 12 h, mi-
grated cells were stained and quantified. The results represent the means± SEM of three different experiments. *P＜ 0.01 compared to the control. (B) 
HUVECs were treated with various concentrations of cathepsin L for 30 min. Equal amounts of protein were separated by SDS-PAGE gel, and immuno-
blot analysis was performed. (C) HUVECs were pretreated with a JNK inhibitor, SP600125 (25 μM), for 1 h. Then cell migration was stimulated by addi-
tion of cathepsin L (100 ng/ml). After 12 h, migration assay was performed in the same way as above (A). The results represent the means± SEM of 
three different experiments. *P＜ 0.01 compared to the cathepsin L group.
SP600125, significantly inhibited the cell migration 
induced by cathepsin L in HUVECs.
Discussion
Several studies have revealed the roles of bFGF in 
angiogenesis, including endothelial cell prolife-
ration and migration. In response to bFGF, a large 
number of cellular signaling processes occur in 
order to regulate cellular events, including cell pro-
liferation and migration (Turner and Grose, 2010). 
The bFGF has also proved to be a promising 
therapeutic agent in treating myocardial and hindlimb 
ischemia (Ninomiya et al., 2003; Nishikage et al., 
2004). Most in vivo studies have reported that 
bFGF gene delivery improves the functional out-
come in ischemic models; however, the focus has 
only been on the autocrine effect of bFGF in 
endothelial cells. Because, in the case of in vivo 
gene transfer for ischemic limb diseases, intra-
muscular injection of a viral vector or plasmid DNA 
is used for gene delivery to an intact skeletal 
muscle, paracrine factors released from these 
tissues may play an important role in endothelial 
cell proliferation and migration. 
   The results of the present study provide impor-
tant evidence in support of roles for factors released 
from SkMCs transfected with the bFGF gene in the 
regulation of endothelial cell migration. The main 
finding of this study is that mere bFGF accumula-
tion in the bFGF-CM is not sufficient to induce 
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endothelial migration. We found that bFGF-CM 
from SkMCs significantly induced HUVEC migration, 
which was reduced when a bFGF-neutralizing anti-
body was added to the conditioned media. How-
ever, it is important to note that cell migration did 
not completely decline to the control level in the 
bFGF antibody-treated group, indicating that other 
secreted factors in the bFGF-CM also affect endo-
thelial cell migration. We identified several proteins 
secreted from SkMCs in response to bFGF 
stimulation using 1-D gel electrophoresis and mass 
spectrometry. The increased production of three 
factors, MMP-1, PAI-1, and cathepsin L, in the 
bFGF-CM of SkMCs cells was confirmed by RT- 
PCR and immunoblot analysis (Figure 3). Because 
bFGF exerts its effects through its transmembrane 
receptor, production of these factors may result 
from the autocrine effect in response to bFGF 
released from SkMCs transfected with the bFGF 
gene. Indeed, a marked enhancement of mRNA 
expression and protein levels was observed in 
SkMCs treated with bFGF protein (Figure 4). The 
induction of these three factors by Ad/bFGF infec-
tion significantly decreased in the presence of the 
bFGF neutralizing antibody in SkMCs (Supple-
mentary Figure 2). 
   One of the factors identified in our study is 
MMP-1, a zinc-dependent proteolytic enzyme involved 
in the remodeling of the extracellular matrix and 
the proteolytic processing of interstitial collagenase 
for the degradation of connective tissue (Pardo 
and Selman, 2005). MMP-1 contributes to physio-
logical processes, such as tissue repair, regene-
ration, and invasion (Pulukuri and Rao, 2008) and 
it also directly promotes tube formation of endo-
thelial cells. This suggests MMP-1 is associated 
with pro-angiogenic events (Blackburn and Brinckerhoff, 
2008). Research regarding the effects of bFGF on 
MMP-1 expression has demonstrated that bFGF 
administration increase MMP-1 expression in human 
periodontal ligament cells (Palmon et al., 2000). An 
increase of MMP-1 protein was also observed 
when bFGF was added to human skin fibroblasts 
(Xie et al., 2008). Our study shows that overexpre-
ssion of bFGF leads to upregulation of MMP-1 in 
SkMCs and that stimulation of SkMCs with bFGF 
protein also results in increased MMP-1 expression 
and secretion. In addition, we have demonstrated 
that MMP-1 from bFGF-conditioned media plays 
an important role in endothelial cell migration 
(Figure 5A). Its effect on cell migration was con-
firmed by treating HUVECs with MMP-1 protein 
(Figure 6A), indicating direct a role for endothelial 
cell migration and supporting important roles such 
as cell invasion and matrix degradation in angio-
genesis. 
   PAI-1, a regulator of both tissue-type plasminogen 
activator (t-PA) and urokinase plasminogen acti-
vator (uPA), has also been shown to play a multi-
functional role in various processes associated 
with vascular remodeling (Nicholl et al., 2006; 
Binder et al., 2007). PAI-1 also plays a crucial role 
in the cell adhesion and migration of vascular cells 
and in angiogenesis (Agirbasli, 2005; Binder et al., 
2007). However, controversial data about the 
proangiogenic and antiangiogenic effects of PAI-1 
have been described. It is likely that PAI-1 func-
tions depending on the experimental conditions 
and interactions with different molecules. In fact, 
the angiogenic response of PAI-1 was shown to 
depend on its concentration. In other words, PAI-1 
is proangiogenic at physiological concentrations 
and antiangiogenic at higher levels (Devy et al., 
2002). But, bFGF definitely increased PAI-1 mRNA 
and the accumulation of PAI-1 protein in vascular 
endothelial cells (Kaneko et al., 2002) and smooth 
muscle cells (Watanabe et al., 2001). Our data 
show that PAI-1 is secreted from SkMCs trans-
fected with bFGF, and it influences the migration of 
HUVECs. The induction of uPA was also observed 
in SkMCs treated with bFGF (Supplementary 
Figure 3). These results in turn could account, at 
least in part, for the stimulatory effect of the 
uPA-PAI-1 complex in bFGF-induced endothelial 
migration.
   Of particular interest in this study is the role of 
cathepsin L in endothelial cell migration. The 
involvement of PAI-1, uPA, and MMPs in endo-
thelial migration and angiogenesis is documented, 
but a possible role of cathepsin L has not yet been 
addressed. Cathepsin L, a lysosomal protease, 
plays an important role in intracellular protein 
degradation. It is secreted from the cell under 
certain conditions (Collette et al., 2004). Cathepsin 
L has also been shown to contribute to tumor cell 
invasion (Yang and Cox, 2007), metastasis (Lah et 
al., 2006), and malignancy (Skrzydlewska et al., 
2005). Urbich et al. have reported that cathepsin L 
has a critical role in vasculogenesis by promoting 
the invasive activity of endothelial progenitor cells. 
Moreover, they showed that transfection with 
cathepsin L resulted in an increased invasive 
capacity in HUVECs (Urbich et al., 2005). The 
identification of cathepsin L as a stimulator of 
endothelial cell migration is interesting from a 
biological point of view. Above all, bFGF induces 
significant increases in cathepsin L in SkMCs 
(Figure 3, Supplementary Figure 4), and most 
importantly the cathepsin L effect is required for 
bFGF-induced endothelial cell migration. Another 
finding of the present study is that endothelial cell 
migration by cathepsin L is mediated through the 
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JNK pathway (Figure 6, Supplementary Figure 5). 
Since the direct role of cathepsin L on endothelial 
cells and its action mechanism have not been well 
demonstrated, our study may encourage the consi-
deration of a novel function of this protease. We 
cannot rule out the possibility of the association of 
cathepsin L with other proteins in the regulating 
endothelial migration because cathepsin L can 
generate potent antiangiogenic molecule, such as 
endostatin (Felbor et al., 2000). Therefore, further 
studies will be necessary to investigate how cathe-
psin L production is regulated in response to bFGF 
and whether cathepsin L also affects the expre-
ssion of other proteins in endothelial cells. In 
summary, we have shown that several factors are 
secreted from bFGF-overexpressed SkMCs, which 
promote endothelial cell migration. In particular, we 
report here, for the first time, that cathepsin L plays 
a direct and crucial role in endothelial cell migration 
and that this effect is mediated through the 
activation of the JNK pathway.
Methods
Materials 
Anti-human bFGF antibody and bFGF-neutralizing anti-
body were purchased from Millipore (Bedford, MA). Anti- 
MMP-1 antibody was purchased from Chemicon (Temecula, 
CA). Anti-PAI-1 and anti-cathepsin L antibodies were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-phospho-p38, anti-phospho-JNK, and anti-phospho-ERK 
antibodies were purchased from Cell Signaling (Beverly, 
MA). Recombinant MMP-1 protein and bFGF protein were 
purchased from R&D Systems (Minneapolis, MN) and 
Invitrogen (Camarillo, CA), respectively. PAI-1 and cathep-
sin L proteins were purchased from Calbiochem (San 
Diego, CA). Neutralizing antibodies against MMP-1 and 
PAI-1, and cell-impermeable cathepsin L inhibitor (cathepsin 
inhibitor II, Z-Phe-Tyr-CHO) were also purchased from 
Calbiochem. Human MMP-1 and cathepsin L ELISA kits 
were from R&D Systems. Human PAI-1 ELISA kit was 
obtained from Abfrontier (Seoul, Korea). SB203580 and 
PD98059 were purchased from AG Scientific (San Diego, 
CA). SP600125 was procured from Calbiochem.
Cell culture 
SkMCs (Lonza, Walkersville, MD) were cultured in SKGM 
(Lonza) with supplements on a 5% CO2 atmosphere at 
37oC. HUVECs (Lonza) were maintained in EBM-2 medium 
(Lonza) supplemented with 2% fetal calf serum (FCS), 
according to manufacturer’s instructions. For all experi-
ments, cells were used up to the ten passages and har-
vested at 90% confluence.
Preparation of adenoviral vector
A recombinant cDNA for the secreted form of human bFGF 
was constructed by adenovirus expression vector kit 
(Takara Bio, Shiga, Japan). The bFGF cDNA was placed 
into a cosmid vector (pAxCAwt) which contains potent 
CAG promoter and nearly the full-length adenovirus 
genome deficient E1 and E3 genes. This cosmid vector 
inserted with bFGF DNA and DNA-TPC digested with a 
restriction endonuclease EcoT22I (Takara Bio) were 
co-transfected into 293 cells. Recombinant adenovirus was 
generated by homologous recombination according to 
manufacturer’s instructions. The recombinant adenovirus 
Ad/bFGF was purified by ultra-centrifugation through a 
CsCl2 gradient followed by extensive dialysis. The titer of 
the virus stock was assessed by a plaque-formation assay 
using the 293 cells and expressed in plaque formation 
units. The control adenovirus Ad/LacZ expressing bacterial 
β-galactosidase was also constructed by same method. 
Preparation of conditioned media
Human SkMCs were grown in SKGM in the presence of 
10% fetal bovine serum (FBS) until 80-90% confluence. 
The growth medium was then removed, cells were 
incubated in basal media (SKBM, Lonza) containing 0.1% 
BSA for 16 h. Cells were then infected with Ad/bFGF (10 
moi) or Ad/LacZ. After 6 h, cells were washed twice with 
SKBM and incubated at 37oC in a humidified atmosphere 
of 5% CO2 for 72 h. Conditioned media from Ad/bFGF- 
infected cells (bFGF-CM), Ad/LacZ-infected cells (LacZ- 
CM) or uninfected cells (control-CM) were then collected, 
centrifuged for 10 min at 3,000 × g to remove cell debris 
and stored at -80oC. The amount of secreted bFGF in the 
conditioned medium was measured with the human bFGF 
ELISA kit (R&D Systems), according to the manufacturer’s 
instructions. 
Cell migration assay
HUVECs (1×105 cells) were seeded into 8.0-μm pore 
transwell inserts (Corning, Corning, NY). Inserts containing 
HUVECs were placed into a 24-well plate containing basal 
medium (EBM-2) with 0.2% FBS. HUVECs migration was 
stimulated by addition of 1 ml of 5× conditioned media 
(bFGF-CM or LacZ-CM) or 2 ng/ml of bFGF protein to the 
lower well of the Boyden chamber. After 12 h, the surface 
of the upper membrane was swabbed with a cotton-tipped 
applicator to remove non-migrating cells. Inserts were fixed 
in methanol for 30 min and stained with 1% crystal violet 
for 2 h. For quantitative analysis, the surface of membrane 
was eluted by methanol and optical density was measured 
using a microplate reader. 
RT-PCR
Total RNA from SkMCs was isolated using the RNA 
extraction reagent Trizol (Invitrogen). RNA samples were 
reverse-transcribed using oligo-dT primer and Moloney 
murine leukemia virus reverse transcriptase (Gibco BRL, 
Grand Island, NY) at 42oC for 2 h. Then the cDNAs were 
amplified by PCR in the presence of each specific primer 
and Taq DNA polymerase. The cDNA fragments corres-
ponding to bFGF, MMP-1, PAI-1 and cathepsin L were 
amplified with the following sets of primers: 5'-GAGGA 
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GTTGTGTCTATCAAAG-3' and 5'-GTTCGTTTCAGTGCCA 
CATACC-3' for bFGF, 5'-GGATTGAAAATTACACG-3' and 5'- 
CTTTCATCTTCATCAAAATG-3' for MMP-1, 5'-CAGACCA 
AGAGCCTCTCCAC-3' and 5'-ATCACTTGGCCCATGAA 
AAG-3' for PAI-1, 5'-GTCAGTGTGGTTCTTGTTGG-3' and 
5'-AAGGACTCATGACCTGCATC-3' for cathepsin L, and 5'- 
CGTGGGCCGCCCTAGGCACCA-3' and 5'-TTGGCCTTA 
GGGTTCAGGGGGG-3' for β-actin. The PCR products were 
electrophoresed on 1.5% agarose gels. Each DNA band 
was visualized by staining with ethidium bromide and 
quantified by densitometer using TINA-image analysis pro-
gram.
SDS-PAGE and immunoblot analysis 
Cell lysates containing equal amounts of protein were 
subjected to SDS-polyacrylamide gel electrophoresis, and 
the proteins transferred to polyvinylidene difluoride (PVDF) 
membranes. After blocking in 10 mM Tris-Cl buffer (pH 8.0) 
containing 150 mM sodium chloride, 0.1% Tween 20, and 
5% (w/v) non-fat dry milk, the membranes were treated 
with primary antibodies, followed by appropriate horse-
radish peroxidase-conjugated secondary antibodies. The 
antigen-antibody bands were detected with a Western 
Blotting Luminol Reagent kit (Santa Cruz Biotechnology) 
following manufacturer’s instruction.
One-dimensional gel electrophoresis and silver 
staining 
Conditioned media were collected and concentrated ten 
times, and proteins were electrophoresed through an 8- 
16% gradient polyacrylamide precast gel (Bio-Rad). The 
gel was then stained using Silver Stain Plus kit (Bio-Rad). 
The gel was first fixed in a fixative enhancer solution (50% 
methanol, 10% acetic acid and 10% fixative enhancer 
concentrate) for 20 min. The gel was then washed twice in 
deionized distilled water for 10 min. The Gel was incubated 
in the staining solution (5% sliver complex solution, 5% 
reduction moderator solution, 5% image development 
reagent and 50% development accelerator solution) until 
proteins were visible. 
Mass spectrometry and protein identification
Individual protein bands were excised, chopped into 1-mm2 
pieces. Proteins were subjected to in-gel trypsin digestion. 
Excised gel spots were destained with 100 ml of destaining 
solution (50% MeOH in 10% acetic acid) with shaking for 5 
min. After removal of the solution, gel spots were incu-
bated with 200 mM ammonium bicarbonate for 20 min. The 
gel pieces were dehydrated with 100 ml of acetonitrile and 
dried in a vacuum centrifuge. The gel pieces were rehy-
drated with 20 ml of 50 mM ammonium bicarbonate 
containing 0.2 mg modified trypsin (Promega, Madison, 
WI) for 45 min on ice. After removal of solution, 30 ml of 50 
mM ammonium bicarbonate was added. The digestion was 
performed overnight at 37oC. The peptide solution was 
desalted using C18 nano column (home-made). Custom- 
made chromatographic columns were used for desalting 
and concentration of the peptide mixture prior to mass 
spectrometric analysis. A column consisting of Poros 
reverse phase R2 material (20-30 μm bead size, PerSeptive 
Biosystems, Foster City, CA) was packed in a constricted 
GELoader tip (Eppendorf, Hamburg, Germany). Ten micro-
liters of the peptide mixture from the digestion supernatant 
was diluted 30 μl in 0.1% TFA, loaded onto the column, 
and washed with 30 μl of 0.1% TFA. The peptides were 
eluted by 0.8 μl of matrix solution (70% acetonitrile, 0.1% 
TFA, 10 mg/ml alpha-cyano-4-hydroxycinamic acid). The 
eluted peptides were spotted onto a stainless steel target 
plate. Masses of peptides were determined using MALDI- 
TOF mass spectrometer (Model M@LDI-R; Micromass, 
Manchester, UK). Calibration was performed using internal 
mass of trypsin. Peptide masses were matched with the 
theoretical peptides of all proteins in the NCBI database 
using Mascot search program (www.matrixscience.com).
Statistical analysis
Data were expressed as means ± S.E.M. Statistical com-
parisons were performed by one-way analysis of variance 
and Student’s t-test. Differences were considered signifi-
cant at P＜ 0.05.
Supplemental data
Supplemental data include five figures and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-43-4-02.pdf.
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